Skip to content
March 29, 2024

Equity.Guru

Investment information for the new generation

Search

2016

Biotech flailer Hemostemix (HEM.V) took a punch to its distended gut today as a sell-off of the embattled stock cut the share price of the company by nearly half,…
Sometimes I can’t even. For a few years now, Lexaria Bioscience (LXX.C) has crept around in the background of the Canadian bongosphere. It had a chequered start, partnering up with…
Investing in fashion is a rough business at the best of times. One day you’re the hot brand that nobody can stop seeing on the runway and red carpet,…
Last week, on the recommendation of the CEO of upcoming listing Peekaboo Beans (NOR.V) who raised early financing there, I took a hard look at a private equity funding…
In a move that’s so ‘wow’, I can barely fathom it, dysfunctionally-run newspaper conglomerate Postmedia (PNC.B, but don’t bother trying to buy shares as they’re largely decorative at this…
Reviving an old series based around who’s doing deals downtown today, this is today’s Friday recap on who I’ve been chatting with over the past week. And as you’ll…
Okay, this is time sensitive, so don’t screw around. I’m not normally a private equity guy, but over at the private equity investment site FrontFundr.com, you can buy shares…
A post aimed at those of you who are new to the site and/or new to the market. May also prove interesting to existing market technicians. Enjoy. In the…
Two things jumped out today in the US weed scene that made me realize why I hate the US weed scene so much, and both deserve unending scorn. First,…
A few weeks ago, I started a new column for VancouverIsAwesome.com, a BC-based online news and events outfit aimed squarely at two demographics the Vancouver – and greater Canadian…